Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  XenoPort, Inc.    XNPT

No quotes available
-- USD   0.00%
07/05 XENOPORT : Arbor Pharmaceuticals Completes Successful Tender Offer f..
06/21 LAWSUIT FOR INV : XNPT) in Effort to Halt Acquisition Filed
06/16 XENOPORT : Arbor Pharmaceuticals and XenoPort Announce the Expiratio..
News SummaryMost relevantAll newsSector news 

XenoPort, Inc. : XenoPort Announces New Employment Inducement Award

share with twitter share with LinkedIn share with facebook
share via e-mail
06/01/2012 | 11:05pm CEST

XenoPort, Inc. (Nasdaq:XNPT) reported today that an equity award was made to a new employee subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan. The employee, Sayuri Ino, was granted restricted stock units representing an aggregate of 500 shares of XenoPort's common stock. The restricted stock units vest in four equal annual installments on anniversaries of the June 1, 2012 grant date. The equity award was approved by the independent compensation committee of XenoPort's board of directors and was granted as an inducement material to the new employee entering into employment with XenoPort in accordance with Nasdaq Market Place Rule 5635(c)(4).

About XenoPort

XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is XenoPort's first U.S. Food and Drug Administration-approved product. GlaxoSmithKline holds commercialization rights and certain development rights for Horizant in the United States. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved for the treatment of moderate-to-severe primary restless legs syndrome in Japan. Astellas Pharma Inc. holds all development and commercialization rights for Regnite in Japan and five other Asian countries. XenoPort holds all other world-wide rights and has co-promotion and certain development rights to gabapentin enacarbil in the United States. XenoPort's pipeline of product candidates includes potential treatments for patients with postherpetic neuralgia, spasticity and Parkinson's disease.

To learn more about XenoPort, please visit the company Website at www.XenoPort.com.

Horizant is a registered U.S. trademark of GSK.

XENOPORT is a registered trademark of XenoPort, Inc.

Regnite is a registered trademark of Astellas.


XenoPort, Inc.
Jackie Cossmon, 408-616-7220

© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on XENOPORT, INC.
07/05 XENOPORT INC : Completion of Acquisition or Disposition of Assets, Notice of Del..
07/05 XENOPORT : Arbor Pharmaceuticals Completes Successful Tender Offer for Shares of..
06/21 LAWSUIT FOR INVESTORS IN XENOPORT, I : XNPT) in Effort to Halt Acquisition Filed
06/16 XENOPORT : Report Summarizes Restless Legs Syndrome Study Findings from XenoPort..
06/16 XENOPORT : New Postherpetic Neuralgia Study Results from XenoPort, Inc. Describe..
06/16 XENOPORT : Arbor Pharmaceuticals and XenoPort Announce the Expiration of the HSR..
06/09 XENOPORT : XBiotech Appoints Trey Benson as New Commercial Head to Lead Strategi..
06/05 XENOPORT : Why Xenoport, Inc. Stock Jumped 61.1% in May
06/02 XENOPORT : Research Conducted at XenoPort, Inc. Has Provided New Information abo..
06/02 XENOPORT : BioSurplus To Auction Research Equipment from the Laboratories of Xen..
More news
Sector news : Pharmaceuticals - NEC
03:22p Stada shareholder AOC pushes through board reshuffle
12:43a ABBOTT LABORATORIES : Whiplashed investors stay skittish about St. Jude
08/26DJST JUDE MEDICAL : . Jude Denies Claims in Muddy Waters Report
08/26DJALERE : Sues Abbott to Force Merger -- 2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/06 Biotechnology - The Perfect Yo-Yo
07/05 Is This The Next REIT To Return 50%?
07/01 Jay Z Sells Out To Apple
06/16 GE's Next Big Energy Move
06/15 Up 169% In A Year With More To Go
Income Statement Evolution
More Financials
Vincent J. Angotti Chief Executive Officer
William G. Harris Chief Financial Officer & Senior VP-Finance
Richard K. Kim Chief Medical Officer & SVP-Clinical Development
Edward J. Schutter Director
Leslie B. Zacks Co-Secretary & Treasurer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.89%325 679
ROCHE HOLDING LTD.-11.47%214 671
PFIZER INC.7.87%211 206
NOVARTIS AG-9.62%210 234
More Results